These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26783118)

  • 1. Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer.
    Masuda T; Ishikawa T; Mogushi K; Okazaki S; Ishiguro M; Iida S; Mizushima H; Tanaka H; Uetake H; Sugihara K
    Int J Oncol; 2016 Mar; 48(3):975-82. PubMed ID: 26783118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of NUCKS1 as a colorectal cancer prognostic marker through integrated expression and copy number analysis.
    Kikuchi A; Ishikawa T; Mogushi K; Ishiguro M; Iida S; Mizushima H; Uetake H; Tanaka H; Sugihara K
    Int J Cancer; 2013 May; 132(10):2295-302. PubMed ID: 23065711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients.
    Kumar M; Srivastava G; Kaur J; Assi J; Alyass A; Leong I; MacMillan C; Witterick I; Shukla NK; Thakar A; Duggal R; Roychoudhury A; Sharma MC; Walfish PG; Chauhan SS; Ralhan R
    J Transl Med; 2015 Jan; 13():8. PubMed ID: 25591983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of SATB1 as a Specific Biomarker for Lymph Node Metastasis in Colorectal Cancer.
    Baba H; Ishikawa T; Mogushi K; Ishiguro M; Uetake H; Tanaka H; Sugihara K
    Anticancer Res; 2016 Aug; 36(8):4069-76. PubMed ID: 27466515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of osteoprotegerin expression in human colorectal cancer.
    Tsukamoto S; Ishikawa T; Iida S; Ishiguro M; Mogushi K; Mizushima H; Uetake H; Tanaka H; Sugihara K
    Clin Cancer Res; 2011 Apr; 17(8):2444-50. PubMed ID: 21270110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-Scale Analysis of Gene Expression Data Reveals a Novel Gene Expression Signature Associated with Colorectal Cancer Distant Recurrence.
    Alajez NM
    PLoS One; 2016; 11(12):e0167455. PubMed ID: 27935967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer.
    Matsuyama T; Ishikawa T; Mogushi K; Yoshida T; Iida S; Uetake H; Mizushima H; Tanaka H; Sugihara K
    Int J Cancer; 2010 Nov; 127(10):2292-9. PubMed ID: 20162577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A2, a potential marker for early recurrence in early-stage oral cancer.
    Tsai ST; Jin YT; Tsai WC; Wang ST; Lin YC; Chang MT; Wu LW
    Oral Oncol; 2005 Apr; 41(4):349-57. PubMed ID: 15792606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Proteomic Analysis of Human Cholangiocarcinoma Cell Lines: S100A2 as a Potential Candidate Protein Inducer of Invasion.
    Wasuworawong K; Roytrakul S; Paemanee A; Jindapornprasert K; Komyod W
    Dis Markers; 2015; 2015():629367. PubMed ID: 25999659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial but not stromal expression of collagen alpha-1(III) is a diagnostic and prognostic indicator of colorectal carcinoma.
    Wang XQ; Tang ZX; Yu D; Cui SJ; Jiang YH; Zhang Q; Wang J; Yang PY; Liu F
    Oncotarget; 2016 Feb; 7(8):8823-38. PubMed ID: 26741506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A molecular signature for the prediction of recurrence in colorectal cancer.
    Wang L; Shen X; Wang Z; Xiao X; Wei P; Wang Q; Ren F; Wang Y; Liu Z; Sheng W; Huang W; Zhou X; Du X
    Mol Cancer; 2015 Feb; 14(1):22. PubMed ID: 25645394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma.
    Imazawa M; Hibi K; Fujitake S; Kodera Y; Ito K; Akiyama S; Nakao A
    Anticancer Res; 2005; 25(2B):1247-50. PubMed ID: 15865073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.
    Gao J; Li N; Dong Y; Li S; Xu L; Li X; Li Y; Li Z; Ng SS; Sung JJ; Shen L; Yu J
    Oncogene; 2015 Jul; 34(31):4142-52. PubMed ID: 25362853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas.
    Lee OJ; Hong SM; Razvi MH; Peng D; Powell SM; Smoklin M; Moskaluk CA; El-Rifai W
    Neoplasia; 2006 Oct; 8(10):843-50. PubMed ID: 17032501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer.
    Wang H; Zhang Z; Li R; Ang KK; Zhang H; Caraway NP; Katz RL; Jiang F
    Int J Cancer; 2005 Aug; 116(2):285-90. PubMed ID: 15800916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer.
    Xiao X; Wang L; Wei P; Chi Y; Li D; Wang Q; Ni S; Tan C; Sheng W; Sun M; Zhou X; Du X
    J Transl Med; 2013 Jun; 11():151. PubMed ID: 23787019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of ANO9 in stage II and III colorectal carcinoma.
    Li C; Cai S; Wang X; Jiang Z
    Oncotarget; 2015 Oct; 6(30):29324-34. PubMed ID: 26317553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A2 promotes glycolysis and proliferation via GLUT1 regulation in colorectal cancer.
    Li C; Chen Q; Zhou Y; Niu Y; Wang X; Li X; Zheng H; Wei T; Zhao L; Gao H
    FASEB J; 2020 Oct; 34(10):13333-13344. PubMed ID: 32816365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
    Richman SD; Southward K; Chambers P; Cross D; Barrett J; Hemmings G; Taylor M; Wood H; Hutchins G; Foster JM; Oumie A; Spink KG; Brown SR; Jones M; Kerr D; Handley K; Gray R; Seymour M; Quirke P
    J Pathol; 2016 Mar; 238(4):562-70. PubMed ID: 26690310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.